Affordable Access

deepdyve-link
Publisher Website

A 2-Week Course of Enteral Treatment with a Very Low-Calorie Protein-Based Formula for the Management of Severe Obesity.

Authors
  • Castaldo, Giuseppe1
  • Monaco, Luigi2
  • Castaldo, Laura1
  • Sorrentino, Paolo3
  • 1 Clinical Nutrition Unit, A.O.R.N. "San Giuseppe Moscati", 83100 Avellino, Italy. , (Italy)
  • 2 Ultrasonography Unit, A.O.R.N. "San Giuseppe Moscati", 83100 Avellino, Italy. , (Italy)
  • 3 Liver Unit, A.O.R.N. "San Giuseppe Moscati", 83100 Avellino, Italy. , (Italy)
Type
Published Article
Journal
International journal of endocrinology
Publication Date
Jan 01, 2015
Volume
2015
Pages
723735–723735
Identifiers
DOI: 10.1155/2015/723735
PMID: 26064113
Source
Medline
License
Unknown

Abstract

Background. Multiple weight loss failures among obese patients suggest the design of new therapeutic strategies. We investigated the role of 2-week course of enteral treatment with a very low-calorie protein-based formula in the management of severe obesity. Methods. We evaluated the feasibility, safety, and efficacy of 2-week continuous administration of a protein-based formula (1.2 g/kg of ideal body weight/day) by nasogastric tube in severely obese adults (body mass index (BMI) ≥ 40 kg/m(2)). Results. In total, 364 patients (59% women; BMI = 46.6 ± 7.2 kg/m(2)) were recruited. The intervention was discontinued within 48 hours in 26 patients, due to nasogastric tube intolerance. No serious adverse events occurred. During the first and the second week, 65% and 80% patients, respectively, reported no side effects. All biochemical safety parameters were affected by the intervention, particularly uric acid (+45%) and aminotransferases (+48%). In the other cases the change was negligible. We observed significant weight loss (5.7 ± 2.3%) and improvement in blood pressure and glucose and lipid metabolism parameters (P < 0.001). Conclusions. A 2-week course of enteral treatment with a very low-calorie protein-based formula appeared a feasible, likely safe, and efficacious therapeutic option to be considered for inclusion into a composite weight loss program for the management of severe obesity. This trial is registered with ClinicalTrials.gov Identifier: NCT01965990.

Report this publication

Statistics

Seen <100 times